Harry Shuman - Merus BV Chief Officer
| MRUS Stock | USD 45.49 1.13 2.55% |
Insider
Harry Shuman is Chief Officer of Merus BV
| Address | Uppsalalaan 17, Utrecht, Netherlands, 3584 CT |
| Phone | 31 30 253 8800 |
| Web | https://www.merus.nl |
Latest Insider Transactions
Harry Shuman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Harry Shuman against Merus BV stock is an integral part of due diligence when investing in Merus BV. Harry Shuman insider activity provides valuable insight into whether Merus BV is net buyers or sellers over its current business cycle. Note, Merus BV insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merus BV'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Harry Shuman over two weeks ago Disposition of 7300 shares by Harry Shuman of Merus BV at 57.84 subject to Rule 16b-3 | ||
Harry Shuman over three months ago Disposition of 2500 shares by Harry Shuman of Merus BV at 54.0 subject to Rule 16b-3 | ||
Harry Shuman over three months ago Disposition of 1000 shares by Harry Shuman of Merus BV at 53.224 subject to Rule 16b-3 | ||
Harry Shuman over six months ago Sale by Harry Shuman of 115 shares of Merus BV |
Merus BV Management Efficiency
The company has return on total asset (ROA) of (0.216) % which means that it has lost $0.216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.446) %, meaning that it created substantial loss on money invested by shareholders. Merus BV's management efficiency ratios could be used to measure how well Merus BV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to gain to -0.38 in 2024. At this time, Merus BV's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 94.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael MBA | Syndax Pharmaceuticals | 53 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Karen Alderete | Vaxcyte | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Guizhong Liu | Adagene | 53 | |
| Ronald Evans | Syndax Pharmaceuticals | 75 | |
| Joshua Kazam | Kronos Bio | 47 | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Nicki Vasquez | Sutro Biopharma | 61 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| Crystal MD | Lyell Immunopharma | 63 | |
| Daniel Faga | AnaptysBio | 44 | |
| Gary Lee | Lyell Immunopharma | 47 | |
| Dennis Mulroy | AnaptysBio | 69 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Prof MD | Lyell Immunopharma | N/A | |
| Richard Goold | Lyell Immunopharma | 64 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 |
Merus BV Leadership Team
Elected by the shareholders, the Merus BV's board of directors comprises two types of representatives: Merus BV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merus. The board's role is to monitor Merus BV's management team and ensure that shareholders' interests are well served. Merus BV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merus BV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ashley PharmD, Senior Affairs | ||
| Kathleen Farren, IR Officer | ||
| Gregory Perry, Chief Officer | ||
| Hennie Hoogenboom, CoFounder Advisor | ||
| Alexander Bakker, Chief VP | ||
| Peter JD, Company EVP | ||
| Cecilia Geuijen, Chief VP | ||
| Jillian Connell, VP Communications | ||
| Sven MD, President, CEO | ||
| Cornelis Kruif, CTO VP | ||
| Hui Liu, Chief Business Officer and Head of Merus U.S., Executive Vice President | ||
| Harry Shuman, Chief Officer | ||
| Andrew MD, Consultant | ||
| Shannon Campbell, Executive Officer |
Merus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merus BV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (6.14) % | ||||
| Current Valuation | 2.42 B | ||||
| Shares Outstanding | 68.46 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 98.00 % | ||||
| Number Of Shares Shorted | 8.66 M | ||||
| Price To Earning | (4.47) X | ||||
| Price To Book | 4.32 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.